

# Trends in Burden of Cirrhosis and Hepatocellular Carcinoma in US Veterans, 2001–2013

Gastroenterology

149, 1471-1482.e5

DOI: [10.1053/j.gastro.2015.07.056](https://doi.org/10.1053/j.gastro.2015.07.056)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Herbs to treat liver diseases: More than placebo?. <i>Clinical Liver Disease</i> , 2015, 6, 136-138.	1.0	6
2	Veterans Affairs Office of Research and Development: Research Programs and Emerging Opportunities in Digestive Diseases Research. <i>Gastroenterology</i> , 2015, 149, 1652-1661.	0.6	10
3	Universal hepatitis B vaccination: The only way to eliminate hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2015, 63, 1303-1305.	1.8	6
4	Surveillance for Hepatocellular Carcinoma in Patients with NASH. <i>Diagnostics</i> , 2016, 6, 22.	1.3	30
5	Connexin32 deficiency exacerbates carbon tetrachloride-induced hepatocellular injury and liver fibrosis in mice. <i>Toxicology Mechanisms and Methods</i> , 2016, 26, 362-370.	1.3	13
6	Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. <i>Hepatology</i> , 2016, 64, 1969-1977.	3.6	237
7	Why is viral eradication so important in patients with HCV-related cirrhosis?. <i>Antiviral Therapy</i> , 2016, 22, 1-12.	0.6	9
8	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease—hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. <i>Clinical Liver Disease</i> , 2016, 8, 100-104.	1.0	20
9	Capitalising on improved rates of diagnosis of early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 260-261.	1.8	2
10	Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 670-676.	0.7	13
11	Hepatocellular Carcinoma: the Impact of NAFLD. <i>Current Hepatology Reports</i> , 2016, 15, 190-198.	0.4	2
12	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	1.8	36
13	Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. <i>Drug and Alcohol Dependence</i> , 2016, 169, 101-109.	1.6	58
14	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 412-419.e1.	0.6	25
15	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. <i>Gastroenterology</i> , 2016, 151, 457-471.e5.	0.6	195
16	Hepatology after Hepatitis C. <i>Digestive Diseases</i> , 2016, 34, 603-606.	0.8	2
17	The Role of Cholesterol in the Pathogenesis of NASH. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 84-95.	3.1	347
18	Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. <i>Gastroenterology</i> , 2016, 150, 1778-1785.	0.6	251

#	ARTICLE	IF	CITATIONS
19	The Burden of Rehospitalization for Patients With Liver Cirrhosis. <i>Hospital Practice</i> (1995), 2016, 44, 60-69.	0.5	15
20	Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs. <i>American Journal of Medicine</i> , 2017, 130, 432-438.e3.	0.6	75
21	Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, 1090-1099.e1.	0.6	487
22	Shift in disparities in hepatitis C treatment from interferon to <scp>DAA</scp> era: A populationâ€based cohort study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 624-630.	1.0	42
23	Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 32-39.	1.8	121
24	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1201-1212.	1.9	47
25	Reversal of liver fibrosis: From fiction to reality. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 129-141.	1.0	128
26	Implications of <scp>HCV RNA</scp> level at week 4 of direct antiviral treatments for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017, 24, 966-975.	1.0	18
27	Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. <i>American Journal of Gastroenterology</i> , 2017, 112, 1287-1297.	0.2	49
28	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17â€487 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 686-693.	0.8	50
29	Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. <i>BMC Medicine</i> , 2017, 15, 52.	2.3	116
30	Transplantâ€related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 652-662.	1.3	18
31	Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without nonâ€alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1061-1069.	1.9	35
32	Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 93, 395-400.	0.9	11
33	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 67, 1204-1212.	1.8	390
34	Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. <i>Journal of Hepatology</i> , 2017, 66, 504-513.	1.8	82
35	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.	1.9	38
36	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 426-438.	3.6	68

#	ARTICLE	IF	CITATIONS
37	Markedly Increased Rate of Primary Liver Malignancies at Autopsy in Male US Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 316-318.	2.4	2
38	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
39	Liver transplantation for chronic hepatitis C virus infection in the United States 2002–2014: An analysis of the UNOS/OPTN registry. <i>PLoS ONE</i> , 2017, 12, e0186898.	1.1	18
40	Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0181858.	1.1	26
41	Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression. <i>Environmental Toxicology</i> , 2018, 33, 659-669.	2.1	8
42	Dos and Don'ts in the Management of Cirrhosis: A View from the 21st Century. <i>American Journal of Gastroenterology</i> , 2018, 113, 927-931.	0.2	14
43	The high burden of alcoholic cirrhosis in privately insured persons in the United States. <i>Hepatology</i> , 2018, 68, 872-882.	3.6	154
44	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
45	Increased Morbidity and Mortality Associated with Falls Among Patients with Cirrhosis. <i>American Journal of Medicine</i> , 2018, 131, 645-650.e2.	0.6	53
46	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 321-350.	9.6	387
47	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. <i>Drugs and Aging</i> , 2018, 35, 117-122.	1.3	15
48	Nonalcoholic steatohepatitis. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 169-174.	0.8	29
49	Patient-reported outcomes in cirrhosis: A scoping review of the literature. <i>Hepatology</i> , 2018, 67, 2375-2383.	3.6	62
50	The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population. <i>Digestive Diseases and Sciences</i> , 2018, 63, 515-528.	1.1	37
51	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 567-574.e6.	2.4	25
52	Care Coordination in Cirrhosis. <i>Current Hepatology Reports</i> , 2018, 17, 33-41.	0.4	2
53	Changing trends in complications of chronic hepatitis C. <i>Liver International</i> , 2018, 38, 239-247.	1.9	12
54	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018, 38, 258-265.	1.9	34

#	ARTICLE	IF	CITATIONS
55	Transjugular intrahepatic portosystemic shunt as a bridge to non-hepatic surgery in cirrhotic patients with severe portal hypertension: a systematic review. <i>Hpb</i> , 2018, 20, 101-109.	0.1	28
56	HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 25-32.	1.8	393
57	Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 60-70.	0.8	24
58	Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 106-114.e5.	2.4	38
59	Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland. <i>Journal of Public Health and Epidemiology</i> , 2018, 10, 241-250.	0.1	0
60	Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-6.	0.7	154
61	Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals. <i>Cureus</i> , 2018, 10, e2843.	0.2	6
62	Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0204412.	1.1	77
63	Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage. <i>Frontiers in Oncology</i> , 2018, 8, 375.	1.3	11
64	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	0.8	12
65	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1128-1139.e6.	0.6	80
66	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2018, 41, 328-349.	0.0	7
67	Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes. <i>Liver International</i> , 2018, 38, 1882-1890.	1.9	21
68	MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits. <i>Journal of Translational Medicine</i> , 2018, 16, 215.	1.8	12
69	Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments. <i>BMC Gastroenterology</i> , 2018, 18, 112.	0.8	62
70	Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2817.	2.4	557
71	DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2885-2891.	1.0	26
72	Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. <i>Gastroenterology</i> , 2018, 155, 719-729.e4.	0.6	81

#	ARTICLE	IF	CITATIONS
73	Systematic review with meta-analysis: risk of hepatocellular carcinoma in nonalcoholic steatohepatitis without cirrhosis compared to other liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 696-703.	1.9	211
74	Epidemiology of nonalcoholic fatty liver disease-related hepatocellular carcinoma and its implications. <i>JGH Open</i> , 2018, 2, 235-241.	0.7	47
75	Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. <i>Journal of Hepatology</i> , 2018, 69, 1088-1098.	1.8	119
76	Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.	3.6	154
77	Chronic Hepatitis B in US Veterans. <i>Current Hepatology Reports</i> , 2019, 18, 310-315.	0.4	1
78	Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals. <i>Hepatology Communications</i> , 2019, 3, 1124-1136.	2.0	11
79	Access to Comprehensive Services for Advanced Liver Disease in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3471-3479.	1.1	7
80	Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. <i>Epidemiology and Infection</i> , 2019, 147, e193.	1.0	5
81	Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e196412.	2.8	56
82	Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 307-310.	0.7	4
83	Hooray for the VHA! A Survey of Access and Barriers to Liver Care Among Veterans. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3361-3362.	1.1	1
84	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
86	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 1510-1519.	2.0	66
87	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	1.9	77
88	Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G661-G669.	1.6	47
89	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. <i>PLoS ONE</i> , 2019, 14, e0221614.	1.1	6
90	Liver cancer: A leading cause of cancer death in the United States and the role of the 1945-1965 birth cohort by ethnicity. <i>JHEP Reports</i> , 2019, 1, 162-169.	2.6	48
92	Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis. <i>Hepatology</i> , 2019, 70, 403-409.	3.6	29

#	ARTICLE	IF	CITATIONS
93	Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 334-341.	1.4	56
94	Impact of Cirrhosis on Pneumonia-Related Outcomes in Hospitalized Older Veterans. <i>American Journal of the Medical Sciences</i> , 2019, 357, 296-301.	0.4	6
95	Characteristics of Opioid Prescriptions to Veterans With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1165-1174.e3.	2.4	25
96	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. <i>Journal of Hepatology</i> , 2019, 71, 523-533.	1.8	124
97	Epidemiology of Alcohol Use and Alcoholic Liver Disease. <i>Clinical Liver Disease</i> , 2019, 13, 136-139.	1.0	52
98	There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 347-363.	2.3	35
99	Design and rationale of a randomized-controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTFOOD trial. <i>Gastroenterology Report</i> , 2019, 7, 146-149.	0.6	5
100	Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. <i>Hepatology</i> , 2019, 70, 2062-2074.	3.6	35
101	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	0.6	90
102	Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3156.	1.7	25
103	No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 47-52.	0.8	7
104	Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. <i>Gastroenterology</i> , 2019, 156, 1693-1706.e12.	0.6	98
105	Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development. <i>Frontiers in Genetics</i> , 2019, 10, 305.	1.1	26
106	Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals: a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 854-864.	0.8	13
107	Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy. <i>Clinical Liver Disease</i> , 2019, 13, 6-12.	1.0	16
108	Contemporary Epidemiology of Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 244-253.	0.3	19
109	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019, 103, 39-44.	0.5	52
110	Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000342.	1.1	4

#	ARTICLE	IF	CITATIONS
111	Early hospital readmission and survival in patients with cirrhosis: A population-based study. Canadian Liver Journal, 2019, 2, 109-120.	0.3	7
112	HIV and cancer in the Veterans Health Administration System. Seminars in Oncology, 2019, 46, 334-340.	0.8	9
113	Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease—“one of a kind or two different enemies?”. Translational Gastroenterology and Hepatology, 2019, 4, 72-72.	1.5	31
114	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. Gastroenterology & Hepatology (English Edition), 2019, 42, 657-676.	0.0	1
115	Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With Cirrhosis. Annals of Surgery, 2021, 274, e345-e354.	2.1	33
116	Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures. Journal of Clinical Gastroenterology, 2019, 53, e356-e361.	1.1	10
117	Role of Interventional Radiology in Complications of Portal Hypertension. Journal of Clinical Gastroenterology, 2019, 53, 342-349.	1.1	4
118	MELD is the only predictor of short-term mortality in cirrhotic patients with C. difficile infection. Digestive and Liver Disease, 2019, 51, 275-280.	0.4	10
119	Alcohol-Associated Cirrhosis. Clinics in Liver Disease, 2019, 23, 115-126.	1.0	24
120	Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology, 2019, 69, 2150-2163.	3.6	139
121	Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. The Lancet Gastroenterology and Hepatology, 2019, 4, 217-226.	3.7	59
122	Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. American Journal of Gastroenterology, 2019, 114, 98-106.	0.2	36
123	A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction[Link]. Hepatology, 2019, 69, 1219-1230.	3.6	47
124	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. Hepatology, 2019, 69, 1676-1685.	3.6	55
125	The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. Journal of Hepatology, 2019, 70, 674-683.	1.8	420
126	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology, 2019, 156, 254-272.e11.	0.6	1,040
127	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: Clinical and Experimental, 2019, 92, 82-97.	1.5	679
128	Burden of liver diseases in the world. Journal of Hepatology, 2019, 70, 151-171.	1.8	2,125



#	ARTICLE	IF	CITATIONS
129	Symptom-based network classification identifies distinct clinical subgroups of liver diseases with common molecular pathways. <i>Computer Methods and Programs in Biomedicine</i> , 2019, 174, 41-50.	2.6	15
130	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. <i>Hepatology</i> , 2020, 71, 225-234.	3.6	40
131	Predicting 30-Day Hospital Readmission Risk in a National Cohort of Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1003-1031.	1.1	17
132	Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2650-2666.	2.4	580
133	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.	2.4	16
134	Integrated Model for Patient-Centered Advanced Liver Disease Care. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1015-1024.	2.4	19
135	Index admission cholecystectomy for acute biliary pancreatitis favorably impacts outcomes of hospitalization in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 284-290.	1.4	2
136	Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 71, 306-333.	3.6	478
137	Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 379-387.	1.3	9
138	MELD+GRAIL+Na: Glomerular Filtration Rate and Mortality on Liver Transplant Waiting List. <i>Hepatology</i> , 2020, 71, 1766-1774.	3.6	40
139	Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2340-2348.e3.	2.4	16
140	Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. <i>JHEP Reports</i> , 2020, 2, 100061.	2.6	38
141	Risk prediction scores for acute on chronic liver failure development and mortality. <i>Liver International</i> , 2020, 40, 1159-1167.	1.9	22
142	Alcoholic Liver Disease Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. <i>American Journal of Gastroenterology</i> , 2020, 115, 96-104.	0.2	81
143	Screening and Early Detection. , 2020, , 375-398.e7.		1
144	Hepatitis C eradication with direct-acting antivirals reduces the risk of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 364-373.	1.9	22
145	Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. <i>Hepatology</i> , 2020, 71, 2080-2092.	3.6	106
146	Global burden of liver cancer and cirrhosis among children, adolescents, and young adults. <i>Digestive and Liver Disease</i> , 2020, 52, 240-243.	0.4	3

#	ARTICLE	IF	CITATIONS
147	Peptide-based therapy in portal hypertension. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 22-27.	1.2	0
148	Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation</i> , 2020, 104, 104-112.	0.5	14
149	A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2020, 4, 825-833.	2.0	11
150	The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3620.	1.0	6
151	Natural History of Cirrhosis: Changing Trends in Etiology Over the Years. <i>Digestive Diseases</i> , 2021, 39, 358-365.	0.8	10
152	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	1.0	27
153	Carbohydrate Sulfotransferase 4 Inhibits the Progression of Hepatitis B Virus-Related Hepatocellular Carcinoma and Is a Potential Prognostic Marker in Several Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 554331.	1.3	10
154	Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1025-1033.	1.4	11
155	Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2148-2160.e14.	2.4	31
156	Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. <i>Hepatic Oncology</i> , 2020, 7, HEP27.	4.2	40
157	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107706.	1.2	3
158	Burdensome Transitions of Care for Patients with End-Stage Liver Disease and Their Caregivers. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2942-2955.	1.1	19
159	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. <i>JAMA Network Open</i> , 2020, 3, e2015626.	2.8	75
160	Nutrition Parameters for Assessing Malnutrition in a Population of US Veterans With Hepatitis C Virus. <i>Nutrition in Clinical Practice</i> , 2020, 35, 1053-1060.	1.1	2
161	Noninvasive imaging assessment of portal hypertension. <i>Abdominal Radiology</i> , 2020, 45, 3473-3495.	1.0	16
162	Association of physical activity with risk of hepatobiliary diseases in China: a prospective cohort study of 0.5 million people. <i>British Journal of Sports Medicine</i> , 2021, 55, 1024-1033.	3.1	19
163	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. <i>Cancer Communications</i> , 2020, 40, 681-693.	3.7	40
164	Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID-19 Pandemic: A National Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 3186-3193.	2.0	4

#	ARTICLE	IF	CITATIONS
165	Observational and Genetic Associations of Body Mass Index and Hepatobiliary Diseases in a Relatively Lean Chinese Population. <i>JAMA Network Open</i> , 2020, 3, e2018721.	2.8	11
166	Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1397-1405.	1.9	45
167	Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study. <i>Gastroenterology</i> , 2020, 159, 1134-1136.e3.	0.6	69
168	Models for acute on chronic liver failure development and mortality in a veterans affairs cohort. <i>Hepatology International</i> , 2020, 14, 587-596.	1.9	10
169	Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000-2015): A Nationwide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1607.	1.0	2
170	Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study. <i>European Journal of Internal Medicine</i> , 2020, 75, 84-92.	1.0	7
171	The impact of SVR from direct-acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , 2020, 27, 781-793.	1.0	34
172	No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. <i>Gut</i> , 2021, 70, gutjnl-2019-319867.	6.1	24
173	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
174	Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. <i>Hepatology</i> , 2020, 72, 1605-1616.	3.6	431
175	The association between etiology of hepatocellular carcinoma and race/ethnicity in Florida. <i>Liver International</i> , 2020, 40, 1201-1210.	1.9	27
176	Survival benefit associated with early detection of spontaneous bacterial peritonitis in veteran inpatients with cirrhotic ascites. <i>JGH Open</i> , 2020, 4, 503-506.	0.7	2
177	Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data. <i>PLoS ONE</i> , 2020, 15, e0229218.	1.1	26
178	Novel targeted therapies for the management of liver fibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 59-70.	1.0	12
179	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. <i>Journal of Hepatology</i> , 2020, 72, 1062-1069.	1.8	32
180	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	3.7	823
181	Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 40.	1.8	39
182	High levels of dietary methionine improves sitagliptin-induced hepatotoxicity by attenuating oxidative stress in hypercholesterolemic rats. <i>Nutrition and Metabolism</i> , 2020, 17, 2.	1.3	14

#	ARTICLE	IF	CITATIONS
183	&lt;p&gt;Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment&lt;/p&gt;. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 45-76.	1.8	60
184	Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. Clinical and Translational Gastroenterology, 2020, 11, e00139.	1.3	4
185	Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Network Open, 2020, 3, e201997.	2.8	141
186	Hepatitis C Care Continuum in a Human Immunodeficiency Virus (HIV) Positive Cohort: Data From the HIV Atlanta Veterans Affairs Cohort Study. Open Forum Infectious Diseases, 2020, 7, ofaa085.	0.4	7
187	Do Nutritional Interventions Improve the Outcomes of Patients with Cirrhosis and Ascites: a Systematic Review of Randomized Trials. Current Hepatology Reports, 2020, 19, 71-77.	0.4	6
188	Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology, 2021, 73, 219-232.	3.6	59
189	Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Digestive Diseases and Sciences, 2021, 66, 1327-1334.	1.1	3
190	Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record. Digestive Diseases and Sciences, 2021, 66, 1452-1460.	1.1	5
191	Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Annals of Hepatology, 2021, 21, 100225.	0.6	4
192	The Predictive Role of Model for End-Stage Liver Disease-“Lactate and Lactate Clearance for In-Hospital Mortality Among a National Cirrhosis Cohort. Liver Transplantation, 2021, 27, 177-189.	1.3	21
193	Ferritin as a key risk factor for nonalcoholic fatty liver disease in children with obesity. Journal of Clinical Laboratory Analysis, 2021, 35, e23602.	0.9	9
194	Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. Hepatology, 2021, 74, 322-335.	3.6	66
195	Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transplantation, 2021, 27, 699-710.	1.3	11
196	Emotion regulation and experiential avoidance moderate the association between posttraumatic symptoms and alcohol use disorder among Israeli combat veterans. Addictive Behaviors, 2021, 115, 106776.	1.7	7
197	Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Transplant Infectious Disease, 2021, 23, e13466.	0.7	7
198	AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review. Clinical Gastroenterology and Hepatology, 2021, 19, 436-445.	2.4	31
199	Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute-““Chronic Liver Failure. Liver Transplantation, 2021, 27, 16-26.	1.3	20
200	Impact of Safety-Net Burden on In-Hospital Mortality and Hospitalization Costs Among Patients with Alcoholic Hepatitis and Alcoholic Cirrhosis. Alcohol and Alcoholism, 2021, 56, 368-375.	0.9	9

#	ARTICLE	IF	CITATIONS
201	Risk Prediction Models for Postoperative Mortality in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 73, 204-218.	3.6	83
202	Epidemiology of Gastrointestinal Diseases. , 2021, , 27-47.		0
203	Cirrhosis: Therapeutic Aspects and Outcome for Hospitalized Patients in Burkina Faso. <i>Open Journal of Epidemiology</i> , 2021, 11, 152-162.	0.2	1
204	Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer. <i>Clinical Liver Disease</i> , 2021, 17, 6-10.	1.0	11
205	Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. <i>Journal of Viral Hepatitis</i> , 2021, 28, 699-709.	1.0	2
206	Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. <i>American Journal of Gastroenterology</i> , 2021, 116, 1465-1475.	0.2	8
207	Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1406-1413.	0.2	2
208	The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. <i>Clinical Therapeutics</i> , 2021, 43, 518-523.	1.1	1
209	Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016). <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	4
210	Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1399-1408.	1.1	5
211	Outcomes of cholecystectomy in US veterans with cirrhosis: Predicting outcomes using nomogram. <i>American Journal of Surgery</i> , 2021, 221, 538-542.	0.9	5
212	Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996â€”2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2060-2067.	0.2	19
213	The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations. <i>Scientific Reports</i> , 2021, 11, 8689.	1.6	5
214	NAFLD and MAFLD as emerging causes of HCC: A populational study. <i>JHEP Reports</i> , 2021, 3, 100231.	2.6	54
215	Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 615.	1.1	6
216	Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 320.	1.3	26
217	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	2.4	94
218	Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial. <i>BMJ, The</i> , 2021, 373, n1022.	3.0	9

#	ARTICLE	IF	CITATIONS
219	Mental health and addiction service use among United States veterans with liver disease nationally in the Veterans Health Administration. <i>Journal of Public Mental Health</i> , 2021, 20, 191-200.	0.8	0
220	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. <i>Contemporary Clinical Trials</i> , 2021, 104, 106367.	0.8	13
221	The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance. <i>Cancers</i> , 2021, 13, 2251.	1.7	12
222	Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. <i>Journal of Hepatology</i> , 2021, 75, 1049-1057.	1.8	36
223	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 689-698.	1.9	8
224	Association between Administration of Antithrombotics and Intraoperative Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 2527.	1.0	0
225	Value-based focused global population health management. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S275-S289.	0.6	3
226	External Validation of the VOCAL Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems. <i>Liver Transplantation</i> , 2021, 27, 961-970.	1.3	17
227	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 949.	2.6	35
228	Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	3
229	Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. <i>Cancers</i> , 2021, 13, 3476.	1.7	13
230	Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. <i>JAMA Internal Medicine</i> , 2021, 181, 1306.	2.6	63
231	Quantification of gastric mucosal microcirculation as a surrogate marker of portal hypertension by spatially resolved subdiffuse reflectance spectroscopy in diagnosis of cirrhosis: a proof-of-concept study. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 60-67.e1.	0.5	1
232	Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1121-e1134.	2.4	12
233	Best Practices in Large Database Clinical Epidemiology Research in Hepatology: Barriers and Opportunities. <i>Liver Transplantation</i> , 2022, 28, 113-122.	1.3	3
234	The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. <i>Infection and Immunity</i> , 2021, 89, e0037621.	1.0	13
235	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2094-2104.	1.1	7
236	NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. <i>Hepatology</i> , 2021, 74, 3330-3344.	3.6	44

#	ARTICLE	IF	CITATIONS
237	Epidemiology and risk-stratification of NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2021, 75, 1476-1484.	1.8	160
238	Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. <i>Hepatology Communications</i> , 2022, 6, 12-35.	2.0	80
239	A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. <i>Pharmacoeconomics - Open</i> , 2022, 6, 9-19.	0.9	5
240	Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 686962.	1.3	18
241	Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?. <i>European Journal of Internal Medicine</i> , 2021, 94, 6-14.	1.0	5
242	Surveillance of patients with cirrhosis remains suboptimal in the United States. <i>Journal of Hepatology</i> , 2021, 75, 856-864.	1.8	20
243	Impact of Inpatient Attending Specialty and Gastroenterology Consultation on Quality of Care of Patients Hospitalized with Decompensated Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1270-1277.e2.	0.6	3
244	Secreted matrix metalloproteinase-14 is a predictor for antifibrotic effect of IC-2-engineered mesenchymal stem cell sheets on liver fibrosis in mice. <i>Regenerative Therapy</i> , 2021, 18, 292-301.	1.4	4
245	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. <i>JAMA Network Open</i> , 2020, 3, e2023780.	2.8	45
246	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.2	12
247	Alcohol-associated Cirrhosis and Alcoholic Hepatitis Hospitalization Trends in the United States. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 174-179.	1.1	26
248	Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. <i>Transplantation</i> , 2022, 106, 72-84.	0.5	8
249	Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. <i>Gastroenterology Research</i> , 2018, 11, 333-339.	0.4	8
250	Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. <i>World Journal of Gastroenterology</i> , 2016, 22, 2494.	1.4	45
251	C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population. <i>World Journal of Gastroenterology</i> , 2018, 24, 3663-3670.	1.4	24
252	Impact on 30-d readmissions for cirrhotic patients with ascites after an educational intervention: A pilot study. <i>World Journal of Hepatology</i> , 2019, 11, 701-709.	0.8	2
253	Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. <i>Gut and Liver</i> , 2020, 14, 537-545.	1.4	38
254	Current epidemiology in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1295-1307.	1.4	107

#	ARTICLE	IF	CITATIONS
255	Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3623-3631.	1.1	12
256	Ribavirin Improves NK Cell IFN $\gamma$ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2226-2238.	0.5	4
257	FIB-4 Score as a Useful Screening Test for Diagnosing Liver Fibrosis. <i>Journal of Laboratory Medicine and Quality Assurance</i> , 2017, 39, 16-22.	0.1	1
258	Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	1
260	Descriptive Usability Study of CirrODS: Clinical Decision and Workflow Support Tool for Management of Patients With Cirrhosis. <i>JMIR Medical Informatics</i> , 2019, 7, e13627.	1.3	8
261	Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017. <i>Annals of Hepatology</i> , 2021, 26, 100565.	0.6	3
262	Intravenous Albumin in Patients With Cirrhosis: Evaluation of Practice Patterns and Secular Trends of Usage in Ontario 2000 to 2017. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 179-185.	0.1	2
263	Alarming rate of 30-day hospital readmissions in patients with liver cirrhosis. <i>Annals of Translational Medicine</i> , 2021, 9, 0-0.	0.7	0
264	Epidemiology of Gastrointestinal Diseases. , 2020, , 1-21.		1
265	Artificial Intelligence Pipeline to Bridge the Gap between Bench Researchers and Clinical Researchers in Precision Medicine. <i>Med One</i> , 2020, 5, .	1.5	1
266	Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy. <i>Southern Medical Journal</i> , 2020, 113, 578-584.	0.3	1
267	Older Patients With Hepatocellular Carcinoma Are Less Knowledgeable About Survivorship Issues. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 88-92.	1.1	2
268	The Effect of Hospital Safety-Net Burden and Patient Ethnicity on In-Hospital Mortality Among Hospitalized Patients With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 624-630.	1.1	6
269	Alcoholic Liver Disease. <i>Gastroenterology and Hepatology</i> , 2016, 12, 48-50.	0.2	0
270	Hepatitis C Virus and Liver Transplantation. <i>Gastroenterology and Hepatology</i> , 2017, 13, 214-220.	0.2	14
271	Identifying and Treating Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 20-29.	0.6	1
272	Health and Economic Burden of Nonalcoholic Fatty Liver Disease in the United States and Its Impact on Veterans. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 14-19.	0.6	12
273	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, 24-29.	0.6	11



#	ARTICLE	IF	CITATIONS
274	Hepatitis A Virus Prevention and Vaccination Within and Outside the Veterans Health Administration in Light of Recent Outbreaks. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S32-S37.	0.6	1
275	Population Management of Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 72-82.	0.6	2
276	The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6462-6474.	0.0	14
277	External Validation of the FIPS Score for Post-TIPS Mortality in a National Veterans Affairs Cohort. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4581-4589.	1.1	9
278	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
279	Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. <i>Journal of Hepatology</i> , 2022, 76, 1100-1108.	1.8	22
280	A decade of rising alcoholic liver disease hospital admissions and deaths in Irish hospitals, 2007â€“2016. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	3
281	Risk factors for adverse outcomes in emergency versus nonemergency open umbilical hernia repair and opportunities for elective repair in a national cohort of patients with cirrhosis. <i>Surgery</i> , 2022, 172, 184-192.	1.0	7
282	Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4395-4402.	1.1	4
283	Patients With Cirrhosis Who Have a Model for End-stage Liver Disease Sodium Score of 8 or Greater Are at Increased Risk of Poor Outcomes in Operatively Treated Tibia Fractures. <i>Orthopedics</i> , 2022, 45, 79-85.	0.5	2
284	Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. <i>Hepatology</i> , 2022, 76, 404-417.	3.6	11
285	Using Intervention Mapping to Develop a Novel Pain Self-Management Intervention for People with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5063-5078.	1.1	2
286	Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents. <i>Rhode Island Medical Journal (2013)</i> , 2020, 103, 35-40.	0.2	0
287	Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 823491.	1.3	4
288	Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients. <i>JAMA Network Open</i> , 2022, 5, e222427.	2.8	8
289	Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from <i>Curcuma longa</i> in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 368-390.	0.6	10
290	The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. <i>Gastroenterology</i> , 2022, 163, 257-269.e6.	0.6	22
291	Insight into microRNAs-Mediated Communication between Liver and Brain: A Possible Approach for Understanding Acute Liver Failure?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 224.	1.8	5

#	ARTICLE	IF	CITATIONS
292	Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action. PLoS ONE, 2021, 16, e0261377.	1.1	2
293	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	6.1	57
294	Alcohol use disorder in community management of chronic liver diseases. Hepatology, 2023, 77, 1006-1021.	3.6	13
306	Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population. Annals of Surgical Oncology, 2022, 29, 5488-5497.	0.7	5
307	Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease. Clinical Liver Disease, 2022, 20, 61-65.	1.0	1
308	Robust Hepatitis A Vaccination Response Within the United States Veterans Health Administration in the Wake of State Outbreaks. American Journal of Public Health, 2022, 112, 990-994.	1.5	1
309	ASO Author Reflections: Disparities in Utilization of Curative-Intent Therapy for Veterans with Early-Stage HCC. Annals of Surgical Oncology, 0, , .	0.7	0
310	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma, 0, Volume 9, 477-496.	1.8	13
311	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. Seminars in Oncology, 2022, , .	0.8	0
312	The emotional burden of caregiving for patients with cirrhosis. Hepatology Communications, 2022, 6, 2827-2835.	2.0	7
313	Psychosocial Barriers and Their Impact on Hepatocellular Carcinoma Care in US Veterans: Tumor Board Model of Care. , 2022, , .		0
314	Reduction in gut-derived MUFAs via intestinal stearyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma. Hepatology Communications, 2022, 6, 2937-2949.	2.0	7
315	Exploring prognostic value and regulation network of PPP1R1A in hepatocellular carcinoma. Human Cell, 2022, 35, 1856-1868.	1.2	0
316	The burden of liver cirrhosis in mortality: Results from the global burden of disease study. Frontiers in Public Health, 0, 10, .	1.3	37
317	Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019. Journal of Clinical Gastroenterology, 2023, 57, 631-639.	1.1	5
318	Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology, 2023, 77, 489-500.	3.6	13
319	Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population. Annals of Surgical Oncology, 2022, 29, 8413-8420.	0.7	2
320	Performance of risk prediction models for post-operative mortality in patients undergoing liver resection. American Journal of Surgery, 2023, 225, 198-205.	0.9	3

#	ARTICLE	IF	CITATIONS
321	Global cirrhosis prevalence trends and attributable risk factorsâ€“an ecological study using data from 1990â€“2019. <i>Liver International</i> , 2022, 42, 2791-2799.	1.9	4
322	Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis. <i>Current Medical Research and Opinion</i> , 2022, 38, 2163-2173.	0.9	8
323	Type of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration Study. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1632-1640.	1.1	2
324	ASO Author Reflections: Identification of High-Performing Veterans Affairs Health System Regions to Improve Patient Outcomes of Veterans with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
325	Screening of the Key Genes for the Progression of Liver Cirrhosis to Hepatocellular Carcinoma Based on Bioinformatics. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	1
326	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
327	Recognizing skin conditions in patients with cirrhosis: a narrative review. <i>Annals of Medicine</i> , 2022, 54, 3017-3029.	1.5	1
328	Promising hepatoprotective effects of lycopene in different liver diseases. <i>Life Sciences</i> , 2022, 310, 121131.	2.0	6
329	The Liverpool alcoholâ€“related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for England. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 368-377.	1.9	7
330	Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16226.	1.8	12
331	Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	6
332	Dementia Frequently Coexists With Hepatic Encephalopathy but Not Other Cirrhosis Complications in US Veterans. <i>American Journal of Gastroenterology</i> , 2023, 118, 475-480.	0.2	4
333	Plants-based medicine implication in the evolution of chronic liver diseases. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114207.	2.5	7
334	Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up. <i>Wiener Klinische Wochenschrift</i> , 2023, 135, 420-428.	1.0	1
335	Chronic Liver Disease and Cirrhosis are Associated with Worse Outcomes Following SARS-CoV-2 Infection. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 592-600.	0.4	2
336	Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets. <i>Clinical Epidemiology</i> , 0, Volume 15, 349-362.	1.5	0
337	Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. <i>Hepatology Communications</i> , 2023, 7, .	2.0	12
338	The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort study. <i>Hepatology Communications</i> , 2023, 7, .	2.0	0

#	ARTICLE	IF	CITATIONS
339	Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States. <i>Journal of Hepatology</i> , 2023, 79, 329-339.	1.8	3
340	Assessing the risk of surgery in patients with cirrhosis. <i>Hepatology Communications</i> , 2023, 7, .	2.0	5